Delivery Order SPE2DB20D2014-SPE2DB24FC43X
- Not listed
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic 0.25-0.5 mg/dose pens, a medication used to treat diabetes. The contract has a ceiling value of $57,900.75 and a period of performance through April 30, 2025. It is a firm-fixed-price contract, without any set-aside designation, indicating open competition....
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic 0.25-0.5 mg/dose pens, a medication used to treat diabetes. The contract has a ceiling value of $3,519.37 and a period of performance ending on March 26, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the provision of Ozempic 0.25-0.5 mg/dose pens, a medication used to treat type 2 diabetes. The contract has a ceiling value of $13,348.47 and a period of performance through November 28, 2023. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic 0.25-0.5 mg/dose pens, a medication used to treat diabetes. The contract has a ceiling value of $12,582.29 and a performance period through April 2025. It is a firm-fixed-price contract, without any set-aside designation, indicating open competition. AmerisourceBergen Drug...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,849.74 firm fixed-price contract is for the supply of Ozempic 0.25-0.5 mg/dose pens, a medication used to treat type 2 diabetes. The contract has an ultimate completion date of June 4, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Ozempic 0.25-0.5 mg/dose pens, a medication used to treat diabetes. The contract has a ceiling value of $3,370.87 and runs through May 21, 2024. The contract is a firm fixed-price delivery order and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic 0.25-0.5 mg/dose pens, which are used for the treatment of diabetes. The contract has a ceiling value of $42,297.71 and a period of performance through May 31, 2024. The contract is a firm fixed-price agreement and does not have a set-aside designation, indicating open...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the purchase of Ozempic 0.25-0.5 mg/dose pens, a medication used to treat diabetes. The contract has a ceiling value of $15,736 and a period of performance through January 16, 2025. This contract is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distribution company. The contract is for the delivery of Ozempic 0.25-0.5 mg/dose pens, a medication used to treat type 2 diabetes. The contract has a ceiling value of $3,745.49 and a period of performance through April 19, 2024. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic 0.25-0.5 mg/dose pens, a medication used for diabetes management. The contract has a ceiling value of $13,258.75 and runs through December 23, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB24FC43XDelivery Order
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL), a medication used to treat type 2 diabetes. The contract has a ceiling value of $56,324.14 and a period of performance through July 11, 2024. It is a Firm Fixed Price contract, which indicates a predetermined price for the goods or services provided. The contract was not set aside for any specific business category. AmerisourceBergen also holds a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $56.3k | 7/10/24 |